STOCKHOLM, Aug. 18, 2022 /PRNewswire/ --
European approval for Kinpeygo
"On May 19th, the European Medicines Agency (EMA) announced that it had adopted a positive opinion regarding the application for conditional approval of Kinpeygo for the treatment of IgA nephropathy, and on July 15th the European Commission issued the market authorization for Kinpeygo in the European Economic Area (EEA).
